<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692313</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00068487</org_study_id>
    <nct_id>NCT02692313</nct_id>
  </id_info>
  <brief_title>Dose Response of Epinephrine</brief_title>
  <acronym>Epineprhine</acronym>
  <official_title>Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer&#xD;
      duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial&#xD;
      function and atherothrombotic balance in humans. The specific aim of our study will be to&#xD;
      determine the dose response effects of the key ANS counterregulatory hormone epinephrine on&#xD;
      endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in&#xD;
      healthy humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilation (FMD) of the brachial artery</measure>
    <time_frame>From baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp))</time_frame>
    <description>Measurements of FMD will be taken at baseline (pre intervention) and end of glucose clamp (post intervention) and the maximal % change determined</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Saline infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine infusion-0.015ug/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine infusion-0.03 ug/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine infusion-0.06 ug/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Dose response of epinephrine infusion</description>
    <arm_group_label>Epinephrine infusion-0.015ug/kg/min</arm_group_label>
    <arm_group_label>Epinephrine infusion-0.03 ug/kg/min</arm_group_label>
    <arm_group_label>Epinephrine infusion-0.06 ug/kg/min</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline infusion</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline infusion</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy controls age 18-55 yr.&#xD;
&#xD;
          -  Body mass index &gt;21 kg Â· m-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Subjects unwilling or unable to comply with approved contraception measures&#xD;
&#xD;
          -  Subjects unable to give voluntary informed consent&#xD;
&#xD;
          -  Subjects on anticoagulant drugs, anemic or with known bleeding diatheses&#xD;
&#xD;
          -  Subjects with a history of severe, uncontrolled hypertension, heart disease,&#xD;
             cerebrovascular incidents&#xD;
&#xD;
          -  Current tobacco use&#xD;
&#xD;
          -  Subjects with any known allergies to any of the study medications being used&#xD;
&#xD;
        Physical Exam Exclusion Criteria&#xD;
&#xD;
          -  Uncontrolled severe hypertension (i.e., blood pressure greater than 160/100)&#xD;
&#xD;
          -  Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia)&#xD;
&#xD;
          -  Pneumonia treatment or hospitalization within 2 weeks prior to enrollment (study&#xD;
             visit)&#xD;
&#xD;
          -  Hepatic failure / jaundice&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Cerebrovascular accident occurrence or hospitalization within 4 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Fever greater than 38.0 degrees C&#xD;
&#xD;
        Screening Laboratory Tests Exclusion Criteria&#xD;
&#xD;
          -  Hematocrit lower than 32 %&#xD;
&#xD;
          -  White blood cell (WBC) count lower than 3 thou/ul or greater than 14 thou/ul&#xD;
&#xD;
          -  Liver function tests: serum glutamic oxaloacetic transaminase (SGOT) and serum&#xD;
             glutamic-pyruvic transaminase (SGPT) greater than twice upper limit of normal range&#xD;
&#xD;
          -  Alkaline phosphatase greater than 150U/L&#xD;
&#xD;
          -  Total bilirubin (TBil) greater than 2 mg/dl&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Any abnormal cardiac response during multi-stage exercise test (if over 40 years of&#xD;
             age)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Davis, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Tate</last_name>
    <phone>410-706-5643</phone>
    <email>dtate@medicine.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maia Mikeladze, MD</last_name>
    <phone>410-706-5626</phone>
    <email>mmikeladze@medicine.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Tate</last_name>
      <phone>410-706-5643</phone>
    </contact>
    <contact_backup>
      <last_name>Maka Hedrington, MD</last_name>
      <phone>410-706-5636</phone>
    </contact_backup>
    <investigator>
      <last_name>Stephen N Davis, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Stephen N. Davis, MBBS</investigator_full_name>
    <investigator_title>Chairman of Medicine</investigator_title>
  </responsible_party>
  <keyword>epinephrine</keyword>
  <keyword>counterregulation</keyword>
  <keyword>dose responses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

